ArticleJournal of cardiac failure2023
Galectin-3, Acute Kidney Injury and Myocardial Damage in Patients With Acute Heart Failure.
Article in Journal of cardiac failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Challenges of Biomarker Application in Patients with Cardiorenal Syndrome.Biomedicines · 2026Review
- Advances in biomarkers for myocardial injury after non-cardiac surgery.Journal of anesthesia and translational medicine · 2026Review
- Spatial N-glycan rearrangement on αNature communications · 2025Article
- Galectin-3 Is Associated With Risk of Cardiovascular and Kidney Outcomes in Ambulatory Veterans.Kidney medicine · 2025Article
- Worsening Renal Function in Acute Heart Failure: Not Always Harmful.Current heart failure reports · 2025Review
- Galectin-3 as a marker to characterize post-cardiac arrest syndrome in initially survived out-of-hospital cardiac arrest: a prospective two-center study.Resuscitation plus · 2025Article
- The Role of Galectin-3 as a Biomarker in the Cardio-Renal-Metabolic Pathology Axis.Journal of clinical medicine · 2025Review
- Elevated Serum Levels of Galectin-3 and Kidney Injury Molecule-1 as Potential Biomarkers for Early Detection and Staging of Chronic Kidney Disease in Iraqi Population.Reports of biochemistry & molecular biology · 2025Article
- Exploring the Cardiovascular Benefits of Extra Virgin Olive Oil: Insights into Mechanisms and Therapeutic Potential.Biomolecules · 2025Review
- Galectin-3 in acute myocardial infarction: from molecular mechanisms to clinical translation.Frontiers in molecular biosciences · 2025Review
- Article
- Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients.International journal of molecular sciences · 2024Article
- Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review.Journal of cardiovascular translational research · 2024Review
- Association of suPAR, ST2, and galectin-3 with eGFR decline and mortality in patients with advanced heart failure with reduced ejection fraction.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024Article
- Biomarkers in Heart Failure with Preserved Ejection Fraction: A Perpetually Evolving Frontier.Journal of clinical medicine · 2024Review
- Prognostic Value of Serum Galectin-3 for Survival in Patients with Cardiac Light-Chain Amyloidosis.Journal of cardiovascular development and disease · 2024Article
- Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure.Journal of cardiac failure · 2024Article
- Galectin-3 as a Biomarker to Predict Cardiorenal Syndrome in Patients with Acute Heart Failure.Acta Cardiologica Sinica · 2023Article
- The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand?International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 14 institutions in 9 countries.
Funding
Abstract
backgroundGalectin-3, a biomarker of inflammation and fibrosis, can be associated with renal and myocardial damage and dysfunction in patients with acute heart failure (AHF). METHODS AND
resultsWe retrospectively analyzed 790 patients with AHF who were enrolled in the AKINESIS study. During hospitalization, patients with galectin-3 elevation (> 25.9 ng/mL) on admission more commonly had acute kidney injury (assessed by KDIGO criteria), renal tubular damage (peak urine neutrophil gelatinase-associated lipocalin [uNGAL] > 150 ng/dL) and myocardial injury (≥ 20% increase in the peak high-sensitivity cardiac troponin I [hs-cTnI] values compared to admission). They less commonly had ≥ 30% reduction in B-type natriuretic peptide from admission to last measured value. In multivariable linear regression analysis, galectin-3 was negatively associated with estimated glomerular filtration rate and positively associated with uNGAL and hs-cTnI. Higher galectin-3 was associated with renal replacement therapy, inotrope use and mortality during hospitalization. In univariable Cox regression analysis, higher galectin-3 was associated with increased risk for the composite of death or rehospitalization due to HF and death alone at 1 year. After multivariable adjustment, higher galectin-3 levels were associated only with death.
conclusionsIn patients with AHF, higher galectin-3 values were associated with renal dysfunction, renal tubular damage and myocardial injury, and they predicted worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.